ERAS® Guidelines Validation of CRS With or Without HIPEC

Peritoneal Diseases Clinical Trial

Official title: Feasibility and Clinical Results of Implementation of ERAS® Guidelines for Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: an International Prospective Cohort Study

Status Recruiting

Clinical Trial Summary

Enhanced recovery after surgery (ERAS®) pathways have been shown to considerably reduce complications, length of stay and costs after most of surgical procedures by standardised application of best evidence-based perioperative care. Recently an international panel of expert have succeeded to elaborate dedicated recommendations for cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC) in a two-part series of guidelines based on expert consensus (Hübner et al., EJSO, 2020). The aim of this prospective validation study was therefore to study acceptance, feasibility and clinical results of these guidelines in clinical practice.

Hypothesis of the study: Introduction of ERAS® guidelines is feasible and safe. Increasing compliance with ERAS® guidelines (after implementation) will improve recovery and early clinical outcomes of patients undergoing CRS/HIPEC.

Clinical Trial Description

The study includes two succesive phases interrupted by a stage to implement ERAS® guidelines. ;

Related Conditions & MeSH terms

• Peritoneal Diseases

• NCT number: NCT05185791
• Study type: Observational
• Source: Hospices Civils de Lyon
• Contact: Olivier Glehen, MD, PhD
• Phone: +33 478 862 371
• Email: olivier.glehen@chu-lyon.fr
• Status: Recruiting
• Start date: October 1, 2021
• Completion date: August 31, 2022